Pair page
Dihexa with Selank
Mechanism-tag overlap and published literature for Dihexa and Selank, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
angiotensin-iv-analog-hgf-positive-modulatorpeptidomimetic
anxiolytic-nootropictuftsin-analog
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Dihexa and Selank have published these mechanism-level observations. Not a co-administration recommendation.
Tuftsin analog with anxiolytic and immune-modulatory activity. Mechanistically distinct. Sometimes combined with dihexa for "calm focus" — but again, no published evidence supports the specific combination, and selank has its own evidence base on its own merits.
Quick facts
Dihexa
Selank
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2024 | Dihexa | Athira Pharma, Inc. Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease. Press release, late 2024. (NCT04488419 — primary endpoint not met.) | human trial, Phase 2 |
| 2023 | Dihexa | Athira Pharma, Inc. Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton in Parkinson's Disease Dementia and Dementia with Lewy Bodies. Press release, December 2023. (NCT04831281.) | human trial, Phase 2 |
| 2022 | Dihexa | Athira Pharma, Inc. Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease. Press release, 2022. (NCT04491006.) | human trial, Phase 2 |
| — | Dihexa | Hua X, Church K, Walker W, L'Hostis P, Viardot G, Danjou P, Hendrix S, Moebius HJ. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease. (Fosgonimeton Phase 1… | human trial, Phase 1 |
| 2015 | Dihexa | Wright JW, Harding JW. The brain hepatocyte growth factor/c-Met receptor system: A new target for the treatment of Alzheimer's disease. J Alzheimers Dis. 2015;45(4):985-1000. PMID: 25649658. (Mechanistic review.) PMID 25649658 | human study |
| 2021 | Dihexa | Sun X, Deng Y, Liang J, Lin Y, Song J, Zhao S, Zhuang G, Jia Z. AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. Brain Sci. 2021 Oct 28;11(11):1421. PMID: 34827487. (Independent Chinese group; APP/PS1 m… PMID 34827487 | preclinical, in vivo |
| 2025 | Dihexa | FDA. Bulk Drug Substances Nominated for Use in Compounding — 503A and 503B Categories. FDA.gov. Updated 2025–2026. | regulatory / registry |
| 2022 | Dihexa | Stem Cell Research & Therapy. Dihexa as adjunct in peripheral nerve repair. 2022 Apr 11;13(1):159. PMID: 35410439. PMCID: PMC8996222. PMID 35410439 | research article |
| 2015 | Dihexa | Wright JW, Kawas LH, Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases. Prog Neurobiol. 2015 Feb;125:26-46. PMID: 25455861. (Comprehensive Wright/Harding review.) PMID 25455861 | research article |
| 2015 | Dihexa | Uribe PM, Kawas LH, Harding JW, Coffin AB. Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure. Front Cell Neurosci. 2015 Jan 28;9:3. PMID: 25674052. PMCID: PMC4309183. (Independent dihexa hair-cell preservation study.) PMID 25674052 | research article |
| 2015 | Dihexa | Siller R, Greenhough S, Naumovska E, Sullivan GJ. Small-molecule-driven hepatocyte differentiation of human pluripotent stem cells. Stem Cell Reports. 2015 May 12;4(5):939-52. PMID: 25937370. PMID 25937370 | research article |
| 2014 | Dihexa | Benoist CC, Kawas LH, Zhu M, Tyson KA, Stillmaker L, Appleyard SM, Wright JW, Wayman GA, Harding JW. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. J Pharmacol Exp Ther. 2014… PMID 25187433 | research article |
| 2008 | Selank | Zozulia AA, Neznamov GG, Syunyakov TS, et al. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID: 18454096. (Russian Phase… PMID 18454096 | human trial, Phase 3 |
| 2015 | Selank | Medvedev VE, Teresh'chenko OE, Israelyan AY, et al. [Optimization of therapy with traditional anxiolytic drugs in patients with anxiety-asthenic disorders]. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(4):33-40. | human study |
| 2008 | Selank | Uchakina ON, Uchakin PN, Miasoedov NF, et al. [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-75. | human study |
| 2019 | Selank | Inozemtseva LS, Kudryavtseva NN, Bobkova NV, Dolotov OV, Gerasimova OA, Levitskaya NG, Kamensky AA, Andreeva LA, Myasoedov NF, Grivennikov IA. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus… PMID 31625062 | preclinical, in vivo |
| 2017 | Selank | Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Biomed Res Int. 2017;2017:2875904. PMC5322660. | preclinical, in vivo |
| 2008 | Selank | Inozemtseva LS, Karpenko EA, Dolotov OV, Levitskaya NG, Kamensky AA, Andreeva LA, Grivennikov IA. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421:241-243. PMID: 18841778. PMID 18841778 | preclinical, in vivo |
| 2007 | Selank | Semenova TP, Medvinskaia NI, Nesterova IV, Kozlovskaia MM. [Experimental analysis of the effect of Selank on the emotional and cognitive behavior of mice]. Zh Vyssh Nerv Deiat Im I P Pavlova. 2007;57(6):738-743. | preclinical, in vivo |
| 1998 | Selank | Seredenin SB, Kozlovskaia MM, Blednov IuA, Kozlovskii II. [Anxiolytic properties of Selank in BALB/c mice with differences in dopamine system reactivity]. Biull Eksp Biol Med. 1998;126(4):402-406. PMID: 9868709. PMID 9868709 | preclinical, in vivo |
| 2009 | Selank | Russian Federation State Register of Medicines. Selank — 0.15% intranasal solution. Approved 2009. | regulatory / registry |
| 2017 | Selank | Filatova E, Kasian A, Kolomin T, Rybalkina E, Alieva A, Andreeva L, Limborska S, Myasoedov N, Pavlova G, Slominsky P, Shadrina M. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Front Pharmacol. 2017;8:89. PMID… PMID 28316569 | research article |
| 2016 | Selank | Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016;7:31. PMID: 26903861. PMC4757669. PMID 26903861 | research article |
| 2003 | Selank | Kozlovskaya MM, Kozlovskii II, Val'dman EA, Seredenin SB. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neurosci Behav Physiol. 2003;33(7):639-643. PMID: 14552536. PMID 14552536 | research article |
Related pair pages
More research context
Frequently asked
Have Dihexa and Selank been studied together?
Researchers have published mechanistic-level co-administration discussion of Dihexa and Selank. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Dihexa and Selank share?
Dihexa and Selank do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Dihexa and Selank?
Dihexa: Investigational / Research only. Selank: Not approved. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Dihexa and Selank?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Dihexa profile and the Selank profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026